The FDA approved a combination stem cell-gene therapy clinical trial to test the treatment’s ability to slow the progression of amyotrophic lateral sclerosis. It’s the 1st clinical trial to use neural stem cells to deliver a particular protein in the hopes of slowing ALS progression, according to researchers at the ALS clinic at Cedars-Sinai Medical Center.
A progressive neurodegenerative disease, ALS affects nerve cells in the brain and spinal cord and patients eventually lose their ability to control muscle movement. The prognosis is dim – patients are totally paralyzed within 2 to 5 years of diagnosis and the disease is fatal. The ALS Assn. pointed out that there is no cure and only 1 FDA-approved drug that modestly extends survival.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA OKs stem cell, gene therapy trial for ALS appeared first on MassDevice.
from MassDevice http://ift.tt/2ej6AgR
Cap comentari:
Publica un comentari a l'entrada